CN110709106A - 放射性标记的生物分子及其应用 - Google Patents
放射性标记的生物分子及其应用 Download PDFInfo
- Publication number
- CN110709106A CN110709106A CN201880036082.1A CN201880036082A CN110709106A CN 110709106 A CN110709106 A CN 110709106A CN 201880036082 A CN201880036082 A CN 201880036082A CN 110709106 A CN110709106 A CN 110709106A
- Authority
- CN
- China
- Prior art keywords
- compound
- vhh
- biomolecule
- radiolabeled
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762478754P | 2017-03-30 | 2017-03-30 | |
| US62/478,754 | 2017-03-30 | ||
| US201762500692P | 2017-05-03 | 2017-05-03 | |
| US62/500,692 | 2017-05-03 | ||
| US201762529532P | 2017-07-07 | 2017-07-07 | |
| US62/529,532 | 2017-07-07 | ||
| US201762583134P | 2017-11-08 | 2017-11-08 | |
| US62/583,134 | 2017-11-08 | ||
| PCT/IB2018/052211 WO2018178936A1 (en) | 2017-03-30 | 2018-03-29 | Radiolabeled biomolecules and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110709106A true CN110709106A (zh) | 2020-01-17 |
Family
ID=62017598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880036082.1A Pending CN110709106A (zh) | 2017-03-30 | 2018-03-29 | 放射性标记的生物分子及其应用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20200188541A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3600453A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2020512348A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110709106A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018178936A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118388451A (zh) * | 2024-06-28 | 2024-07-26 | 四川大学 | 一种放射性标记的成纤维细胞活化蛋白抑制剂及其制备方法和应用 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102899941B1 (ko) | 2019-05-24 | 2025-12-16 | 듀크 유니버시티 | 18f-방사선 표지된 생체 분자 |
| EP4058423A1 (en) | 2019-11-13 | 2022-09-21 | Duke University | Radiohalogen prosthetic moieties and radiolabeled biomolecules |
| EP3967674A1 (en) * | 2020-09-11 | 2022-03-16 | Precirix N.V. | Reactions of radioactive compounds facilitated by a solid phase |
| EP4337265A4 (en) * | 2021-05-14 | 2026-03-25 | Purdue Research Foundation | TARGETED FOLATE RECEPTOR CONJUGATIONS WITH BRUSH-ON ENZYME-CLEVABLE BINDERS AND METHODS OF USE IN CANCER IMAGING AND TREATMENT |
| KR20240095178A (ko) * | 2021-09-01 | 2024-06-25 | 듀크 유니버시티 | 단백질을 방사성 할로겐으로 부위-특이적 표지하기 위한 시약 및 이의 제조방법 및 사용 방법 |
| AU2023276697A1 (en) | 2022-05-23 | 2024-12-12 | Cereius, Inc. | Her2-binding agents and uses thereof |
| WO2026128025A2 (en) | 2024-07-03 | 2026-06-18 | Solve Therapeutics, Inc. | Anti-ror2 antibody-radionuclide conjugates |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007120251A2 (en) * | 2005-12-22 | 2007-10-25 | Duke University | Stabilized compositions and methods for radiolabeling pharmaceuticals with alpha-particle emitters |
| WO2014179715A1 (en) * | 2013-05-02 | 2014-11-06 | Duke University | Prosthetic compounds for labeling internalizing biomolecules |
| US20160030606A1 (en) * | 2014-07-29 | 2016-02-04 | Vrije Universiteit Brussel | Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5302700A (en) | 1988-05-23 | 1994-04-12 | Duke University | Radiohalogenation conjugate technology |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| EP2247615B1 (en) | 2008-02-14 | 2014-07-30 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind egfr |
| KR101389166B1 (ko) | 2011-01-12 | 2014-04-24 | 미쯔비시 레이온 가부시끼가이샤 | 활성 에너지선 경화성 수지 조성물, 미세 요철 구조체 및 미세 요철 구조체의 제조 방법 |
| KR101279584B1 (ko) | 2011-06-24 | 2013-06-28 | 대한민국 (식품의약품안전처장) | Erbb2 수용체에 선택적으로 결합하는 압타머 및 이의 용도 |
-
2018
- 2018-03-29 JP JP2019553023A patent/JP2020512348A/ja not_active Withdrawn
- 2018-03-29 EP EP18718637.4A patent/EP3600453A1/en active Pending
- 2018-03-29 CN CN201880036082.1A patent/CN110709106A/zh active Pending
- 2018-03-29 US US16/498,264 patent/US20200188541A1/en not_active Abandoned
- 2018-03-29 WO PCT/IB2018/052211 patent/WO2018178936A1/en not_active Ceased
-
2023
- 2023-04-07 JP JP2023062556A patent/JP2023076712A/ja not_active Withdrawn
-
2024
- 2024-11-13 US US18/946,772 patent/US20250073359A1/en active Pending
-
2025
- 2025-02-21 JP JP2025027120A patent/JP2025071280A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007120251A2 (en) * | 2005-12-22 | 2007-10-25 | Duke University | Stabilized compositions and methods for radiolabeling pharmaceuticals with alpha-particle emitters |
| US20090304585A1 (en) * | 2005-12-22 | 2009-12-10 | Duke University | Stabilized Compositions and Methods for Radiolabeling Pharmaceuticals with Alpha-Particle Emitters |
| WO2014179715A1 (en) * | 2013-05-02 | 2014-11-06 | Duke University | Prosthetic compounds for labeling internalizing biomolecules |
| US20160074541A1 (en) * | 2013-05-02 | 2016-03-17 | Duke University | Prosthetic Compounds for Labeling Internalizing Biomolecules |
| US20160030606A1 (en) * | 2014-07-29 | 2016-02-04 | Vrije Universiteit Brussel | Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer |
Non-Patent Citations (3)
| Title |
|---|
| G. VAIDYANATHAN等: "SIB-DOTA: A trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies", 《BIOORGANIC & MEDICINAL CHEMISTRY》 * |
| HIROMICHI AKIZAWA等: "Renal Brush Border Enzyme-Cleavable Linkages for Low Renal Radioactivity Levels of Radiolabeled Antibody Fragments", 《BIOCONJUGATE CHEM.》 * |
| JAEYEON CHOI等: "N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: Influence of isomeric substitution on radiolabeling and target cell residualization", 《NUCLEAR MEDICINE AND BIOLOGY》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118388451A (zh) * | 2024-06-28 | 2024-07-26 | 四川大学 | 一种放射性标记的成纤维细胞活化蛋白抑制剂及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200188541A1 (en) | 2020-06-18 |
| WO2018178936A1 (en) | 2018-10-04 |
| JP2020512348A (ja) | 2020-04-23 |
| US20250073359A1 (en) | 2025-03-06 |
| EP3600453A1 (en) | 2020-02-05 |
| JP2023076712A (ja) | 2023-06-01 |
| JP2025071280A (ja) | 2025-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250073359A1 (en) | Radiolabeled biomolecules and their use | |
| ES2981335T3 (es) | Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes | |
| KR102397783B1 (ko) | Pd-l1 결합 폴리펩티드에 의한 pet 영상화 | |
| Perols et al. | Influence of DOTA chelator position on biodistribution and targeting properties of 111In-labeled synthetic anti-HER2 affibody molecules | |
| US9839704B2 (en) | Prosthetic compounds for labeling internalizing biomolecules | |
| AU2011354599A1 (en) | Radiolabled HER2 binding peptides | |
| CN103402550B (zh) | 用含有18f的有机硅化合物标记的her2结合肽 | |
| JP2015057415A (ja) | 放射免疫コンジュゲートおよびその使用 | |
| US20230340111A1 (en) | Antibody fragment against folr1 | |
| US20230381350A1 (en) | Antibody fragment against fap | |
| JP2024511281A (ja) | 抗cldn18.2抗体コンジュゲート | |
| Nakashima et al. | Development of novel trifunctional chelating agents that enhance tumor retention of radioimmunoconjugates | |
| JP2025522306A (ja) | Her2-結合剤およびその使用 | |
| KR20240099208A (ko) | EGFRvIII-표적화 화합물 및 그의 용도 | |
| WO2026083399A1 (en) | Conjugates and use of same for theranostics | |
| TW202400240A (zh) | 抗vegf抗體的放射性複合體及放射性醫藥 | |
| CA3285616A1 (en) | Method for producing radiolabeled antibody, radiolabeled antibody, and radiopharmaceutical | |
| KR20230163487A (ko) | 항egfr 항체의 방사성 복합체 및 방사성 의약 | |
| CN116077686A (zh) | 可酶切Linker及其用途 | |
| CN119584994A (zh) | 预靶向 | |
| JP2024534909A (ja) | 放射性ハロゲンによるタンパク質の部位特異的標識のための試薬並びにその製造方法及び使用方法 | |
| HK1191244A (en) | Her2 binding peptides labelled with a 18f - containing organosilicon compound | |
| HK1192847A (en) | Radiolabled her2 binding peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |